Key result
uPARAP downregulation attenuates secondary lymphedema by inducing labyrinthine lymphatic vascular remodeling in preclinical models.
Why the study?
Does downregulating uPARAP improve lymphatic vessel architecture and attenuate secondary lymphedema in preclinical models?
Does downregulating uPARAP improve lymphatic vessel architecture and attenuate secondary lymphedema in preclinical models?
Answers are grounded in this paper and cite their sources.
Downregulating uPARAP induces beneficial remodeling of lymphatic vasculature, offering a novel therapeutic pathway for lymphedema.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gucciardo et al. (2025) studied Secondary lymphedema. uPARAP downregulation was evaluated on Secondary lymphedema and lymphatic vessel architecture. Downregulating uPARAP expression induced a beneficial labyrinthine remodeling of lymphatic vasculature that attenuated secondary lymphedema in preclinical models.
Synapse has enriched 10 related papers. Consider them for comparative context: